About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Algernon Health Inc (OP:AGNPF)

0.0346 -0.0079 (-18.59%)

Streaming Delayed Price Updated: 9:30 AM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Algernon Health Inc

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗

April 17, 2024

Via Benzinga

DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design ↗

April 03, 2024

Via Benzinga

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗

August 14, 2023

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

Via Benzinga

DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study ↗

August 08, 2023

Algernon NeuroScience (AGN Neuro), a subsidiary of Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) (CSE:AGN) (FRANKFURT:AGW0), has completed a feasibility study and has finalized its clinical trial design...

Via Benzinga

Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study ↗

July 18, 2022

Via Benzinga

DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up ↗

June 05, 2023

Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous...

Via Benzinga

How To Finance A Psychedelics Business? Learn From These Four Companies ↗

April 04, 2023

Clearmind Medicine Announces Pricing of $3.5 Million Public Offering

Via Benzinga

Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment ↗

April 04, 2023

Canadian biopharma company Algernon Pharmaceuticals Inc.

Via Benzinga

Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More ↗

March 07, 2023

Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...

Via Benzinga

Algernon Pharmaceuticals AP-188 DMT Compound Shows Promise For The Treatment Of TBI ↗

March 03, 2023

In this new podcast, TDR Founder Shadd Dales interviewed Algernon Pharmaceuticals (OTC: AGNPF) CEO, Christopher Moreau.

Via Benzinga

Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program ↗

March 01, 2023

Canadian clinical-stage psychedelics developer Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) will start trading its Class A common shares following a 4-to-1 stock split towards increasing liquidity.

Via Benzinga

Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More ↗

February 27, 2023

Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and...

Via Benzinga

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More ↗

February 21, 2023

Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...

Via Benzinga

Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program ↗

February 21, 2023

Biopharma company Algernon Pharmaceuticals (OTCQB: AGNPF) has launched a new clinical research program via a subsidiary.

Via Benzinga

Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose ↗

February 16, 2023

Algernon Pharmaceuticals (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience has completed the first cohort in its Phase 1 clinical study of

Via Benzinga

A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing ↗

January 18, 2023

Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB: AGNPF)’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed

Via Benzinga

Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One ↗

January 03, 2023

The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs.

Via Benzinga

EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans ↗

December 15, 2022

Part one of a three-part series. The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.

Via Benzinga

Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More ↗

November 21, 2022

Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy

Via Benzinga

Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon ↗

November 16, 2022

Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc.

Via Benzinga

Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University ↗

October 24, 2022

Canadian-based psychedelics biopharma company Algernon Pharmaceuticals Inc.

Via Benzinga

A Foundational Study On Stroke Is Ready. Here Is Why It's Important ↗

September 12, 2022

Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for huma

Via Benzinga

Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment ↗

September 08, 2022

Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has set up a clinical research program for the treatment of strokes, focused on its proprietary DMT analogue, AP-188. The company is also planning to begin...

Via Benzinga

Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution ↗

August 23, 2022

Biotech clinical-stage company Algernon Pharmaceuticals Inc.

Via Benzinga

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

The Week In Psychedelics

Via Benzinga

Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics ↗

September 13, 2021

Last Week In Psychedelics:

Via Benzinga

How To Invest In "Magic Mushrooms" (Psychedelics) ↗

July 09, 2021

A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.

Via Talk Markets

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗

October 13, 2021

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...

Via Benzinga

Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies ↗

July 07, 2021

This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps...

Via Benzinga

Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform ↗

June 21, 2021

Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq...

Via Benzinga

Topics Artificial Intelligence

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Algernon Health Inc (OP:AGNPF)

Headline News about Algernon Health Inc

Sections

Services

Contact Information

Follow Us